Pre-formulation characteristics of ticagrelor: A comprehensive exploration

Ticagrelor is a potent antiplatelet agent that plays a crucial role in preventing cardiovascular events. Preformulation studies are essential in the drug development process to assess the physicochemical properties of the active pharmaceutical ingredient (API) and its suitability for formulation into a final dosage form. This abstract provides an overview of the preformulation studies conducted on Ticagrelor. The preformulation studies encompassed an extensive analysis of Ticagrelor’s physical properties, including solubility, melting point, and crystal structure. Additionally, the drug’s stability under various environmental conditions, such as temperature and humidity, was evaluated. Spectroscopic techniques, such as UV-Vis and FTIR, were used to characterize the chemical structure of the compound. The results of these preformulation studies provide valuable insights into the potential challenges and opportunities in formulating Ticagrelor into stable and bioavailable dosage forms. These findings will guide further formulation development and optimization, ensuring the delivery of an efficacious and safe drug product to patients.